What is the Olanzapine?

Olanzapine is yellowish crystalline powder, while it's Molecular Formula is C17H20N4S. yellowish crystalline powder anti-ulcer, gastrointestinal-emptying agent enhances motility in the upper gastrointestinal tract

What is the CAS number for Olanzapine?

The CAS number of Olanzapine is 132539-06-1.

What is Olanzapine (132539-06-1) used for?

Zyprexa was launched in Canada, Germany, the UK and US as anantipsychotic agent. Prepared in three steps via the intermediate diazepinone, it is anatypical antipsychotic with a high affinity for dopaminergic and serotonergicreceptors. Specifically, olazapine is a potent 5-HT2/D2 antagonist with anticholinergicactivity. It has a greater antagonistic effect at 5-HT2a than at dopamine D2 receptorsand in vivo is clozapine-like. Thus it is less likely to produce extrapyramidal sideeffects and does not produce any granulocytopenia. Its 10 metabolic products are allinactive.InChI:InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Product Class

132539-06-1

Product Name：Olanzapine
Molecular Formula：C₁₇H₂₀N₄S
Purity：99%
Molecular Weight：312.439

Inquiry

Product Details:

CasNo： 132539-06-1

Molecular Formula： C₁₇H₂₀N₄S

Appearance： yellowish crystalline powder

Buy High Grade Olanzapine 132539-06-1 Efficient Transportation

Molecular Formula:C17H20N4S
Molecular Weight:312.439
Appearance/Colour:yellowish crystalline powder
Vapor Pressure:0mmHg at 25°C
Melting Point:195 °C
Refractive Index:1.709
Boiling Point:476.035 °C at 760 mmHg
PKA:7.78±0.20(Predicted)
Flash Point:241.697 °C
PSA：59.11000
Density:1.32 g/cm³
LogP:2.88860

Olanzapine(Cas 132539-06-1) Usage

Description	Olanzapine is an atypical antipsychotic medication that acts by balancing the levels of neurotransmitters, particularly dopamine and serotonin, in the brain. It is sold under the brand name Zyprexa and is available in oral tablet form or as an injection administered into a muscle.
Uses	Schizophrenia: Olanzapine is used to treat the symptoms of schizophrenia, a mental illness characterized by disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions. It is effective for both new-onset disease and long-term maintenance therapy. Bipolar Disorder: Olanzapine may be used alone or in combination with other medications, such as lithium or valproate, to treat manic or mixed episodes associated with bipolar disorder (manic-depressive illness). It helps stabilize mood and reduce the intensity of manic or mixed symptoms. Mechanism of Action: Olanzapine acts by blocking the action of dopamine and serotonin receptors in the brain, thereby regulating neurotransmitter levels. By modulating dopamine and serotonin activity, it helps alleviate symptoms of psychosis, mania, and mood instability associated with schizophrenia and bipolar disorder.
Chemical Properties	Yellow Crystalline Powder
Originator	Lilly (USA)

InChI:InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

132539-06-1 Relevant articles

Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression

Mauricio Tohen, MD, DrPH; Eduard Vieta, MD, PhD; Joseph Calabrese, MD

, Arch Gen Psychiatry. 2003;60(11):1079-1088.

During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P<.001 for all). The olanzapine-fluoxetine group also showed statistically greater improvement than the olanzapine group at weeks 4 through 8.

Direct Reductive Cyclocondensation of the Nitro Group with the Amido Group: Key Role of the Iminophosphorane Intermediate in the Synthesis of 1,4-Dibenzodiazepine Derivatives

Tryniszewski, Micha?,Bujok, Robert,Cmoch, Piotr,Gańczarczyk, Roman,Kulszewicz-Bajer, Irena,Wróbel, Zbigniew

, p. 2277 - 2286 (2019/05/16)

A class of dialkylamino-substituted dibe...

Olanzapine Versus Placebo in the Treatment of Acute Mania

Mauricio Tohen, M.D., Dr.P.H., Todd M. Sanger, Ph.D., Susan L. McElroy, M.D., Gary D. Tollefson, M.D., Ph.D., K.N.

American Journal of Psychiatry, 1999

Olanzapine, a recently introduced novel antipsychotic, demonstrates a pharmacologic profile that most closely resembles that of clozapine (19). In a series of double-blind controlled trials in patients with schizophrenia and schizoaffective disorder, olanzapine appeared superior to the conventional antipsychotic haloperidol on measures of overall psychotic symptoms, negative symptoms, comorbid mood symptoms, and quality of life...

132539-06-1 Process route

: 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine

: 132539-06-1
zyprexa

Conditions

Conditions	Yield
With quinoline p-toluenesulfonate; sulfur; In benzonitrile; at 140 ℃; for 13.5h;	69.5%
With pyridinium p-toluenesulfonate; sulfur; In benzonitrile; at 140 ℃; for 13.5h;	66.6%
With sulfur; 1-methyl-imidazolium p-toluenesulfonic acid; In benzonitrile; at 140 ℃; for 10h;	54.2%
With toluene-4-sulfonic acid; sulfur; In benzonitrile; at 140 ℃; for 9h;	51.7%
With sulfur; triethylamine; In propan-1-ol; dimethyl sulfoxide; at 100 ℃; for 120h;	12%

: 109-01-3
1-methyl-piperazine

: 138564-60-0
4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride

: 132539-06-1
zyprexa

Conditions

Conditions	Yield
at 125 - 145 ℃; for 5 - 12h; Product distribution / selectivity; Neat (no solvent);	84%
at 120 ℃; for 5h;	83.8%
In dimethyl sulfoxide; at 112 - 115 ℃; for 16h;	82%
1-methyl-piperazine; 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride; In dimethyl sulfoxide; at 112 - 115 ℃; for 16h; With pyrographite; In dichloromethane; Product distribution / selectivity; Rapid crystallization;	82%
1-methyl-piperazine; 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride; In dimethyl sulfoxide; at 112 - 115 ℃; for 16h; In dichloromethane; Product distribution / selectivity; Rapid crystallization;	82%
In 1,3-dimethyl-2-imidazolidinone; toluene; at 120 - 130 ℃; for 9 - 11h; Product distribution / selectivity;	76%
1-methyl-piperazine; 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride; In dimethyl sulfoxide; at 112 - 115 ℃; for 16h; With pyrographite; In methanol; dichloromethane; Product distribution / selectivity;	72%
1-methyl-piperazine; 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride; In dimethyl sulfoxide; at 112 - 115 ℃; for 16h; In methanol; dichloromethane; Product distribution / selectivity; Rapid crystallization;	72%
In dimethyl sulfoxide; toluene; for 20h; Reflux; Inert atmosphere;	71%
In dimethyl sulfoxide; toluene; for 24h; Heating;	65%
In dimethyl sulfoxide; at 100 - 120 ℃; for 8h;	61%
In dimethyl sulfoxide; at 138 ℃; for 22h; Product distribution / selectivity; Heating / reflux;	54%
In acetonitrile; at 81 - 82 ℃; for 22h; Product distribution / selectivity; Heating / reflux;	53%
In acetone; at 56 ℃; for 22 - 24h; Product distribution / selectivity; Heating / reflux;	51%
In dimethyl sulfoxide; toluene; at 140 ℃; for 18h;	37%
In dimethyl sulfoxide; toluene;
1-methyl-piperazine; 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride; In dimethyl sulfoxide; toluene; for 20h; Heating / reflux; With ammonia; In dichloromethane; at 25 - 30 ℃; for 0.5h; Product distribution / selectivity; Heating / reflux;
at 120 ℃; for 3h; Product distribution / selectivity;
In dimethyl sulfoxide; toluene;
at 120 ℃; for 3h; Product distribution / selectivity;
In dimethyl sulfoxide; toluene; for 20h; Product distribution / selectivity; Heating / reflux;
In dimethyl sulfoxide; at 120 ℃; for 20h; Product distribution / selectivity;
at 160 ℃; for 0.5h; Sealed tube;	122 mg
at 120 ℃; for 4h;